KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Capital Expenditures: 2017-2025

Historic Capital Expenditures for Amneal Pharmaceuticals (AMRX) over the last 8 years, with Sep 2025 value amounting to $12.3 million.

  • Amneal Pharmaceuticals' Capital Expenditures fell 27.42% to $12.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $63.4 million, marking a year-over-year increase of 36.05%. This contributed to the annual value of $51.9 million for FY2024, which is 20.15% up from last year.
  • Latest data reveals that Amneal Pharmaceuticals reported Capital Expenditures of $12.3 million as of Q3 2025, which was down 46.13% from $22.8 million recorded in Q2 2025.
  • Over the past 5 years, Amneal Pharmaceuticals' Capital Expenditures peaked at $22.8 million during Q2 2025, and registered a low of $5.0 million during Q2 2022.
  • In the last 3 years, Amneal Pharmaceuticals' Capital Expenditures had a median value of $12.0 million in 2023 and averaged $13.0 million.
  • In the last 5 years, Amneal Pharmaceuticals' Capital Expenditures slumped by 40.75% in 2021 and then skyrocketed by 137.73% in 2023.
  • Quarterly analysis of 5 years shows Amneal Pharmaceuticals' Capital Expenditures stood at $17.5 million in 2021, then tumbled by 34.47% to $11.5 million in 2022, then fell by 13.96% to $9.9 million in 2023, then surged by 53.62% to $15.2 million in 2024, then declined by 27.42% to $12.3 million in 2025.
  • Its last three reported values are $12.3 million in Q3 2025, $22.8 million for Q2 2025, and $13.2 million during Q1 2025.